Please try another search
For the nine months ended 31 January 2022, Immunoprecise Antibodies Ltd revenues increased 8% to C$14.1M. Net loss increased from C$2.3M to C$12.1M. Revenues reflect Project revenue segment increase of 7% to C$8.6M, Product sales revenue segment increase of 40% to C$712K, Europe segment increase of 61% to C$6.8M, Other segment increase from C$780K to C$1.6M.
Period Ending: | Jan 31, 2022 | Oct 31, 2021 | Jul 31, 2021 | Apr 30, 2021 |
---|---|---|---|---|
Total Revenue | 4.82 | 4.72 | 4.59 | 4.88 |
Gross Profit | 2.59 | 2.58 | 2.51 | 2.78 |
Operating Income | -4.27 | -4.67 | -3.46 | -2.67 |
Net Income | -3.83 | -5.01 | -3.23 | -5.03 |
Period Ending: | Jan 31, 2022 | Oct 31, 2021 | Jul 31, 2021 | Apr 30, 2021 |
---|---|---|---|---|
Total Assets | 56.45 | 60.33 | 64.44 | 66.96 |
Total Liabilities | 8.76 | 9.43 | 9 | 10.04 |
Total Equity | 47.69 | 50.9 | 55.44 | 56.92 |
Period Ending: | Jan 31, 2022 | Oct 31, 2021 | Jul 31, 2021 | Apr 30, 2021 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -8.13 | -2.98 | -0.96 | -0.6 |
Cash From Investing Activities | -1.11 | -0.45 | -0.34 | -2.46 |
Cash From Financing Activities | -0.18 | -0.13 | -0.21 | 43.38 |
Net Change in Cash | -8.77 | -3.4 | -1.06 | 39.15 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review